Can ultrasound predict cancer drug response earlier?
NCT ID NCT02666690
First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time
Summary
This trial is testing whether contrast-enhanced ultrasound (CEUS) can reliably measure tumor blood flow in people with metastatic cancers like GIST, breast, kidney, colon, rectal, or melanoma. Participants will have two ultrasound scans before starting anti-angiogenic treatment, and again at day 15 and day 30. The goal is to see if the measurements are consistent enough to use CEUS as an early indicator of whether these drugs are working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Contrast-enhanced ultrasound (CEUS)
- What this could lead to
- If the measurements are consistent, CEUS could become a reliable early test for whether anti-angiogenic drugs are working, helping doctors adjust treatment sooner.
- What could go wrong
- This is a small, early-stage variability study, not a treatment test. The results may not translate into routine clinical use, and the technique's reliability could vary across different tumor types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Gustave Roussy Cancer Campus Grand Paris
Villejuif, Val de Marne, 94805, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a flash of radiation tame melanoma skin lesions?
- Could a home workout program reshape the gut and tame chemo toxicity?
- Can targeted radiation boost the power of immunotherapy against melanoma?
- Can delivering cancer drug directly to the liver shrink tumors?
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring